JP2025503969A5 - - Google Patents

Info

Publication number
JP2025503969A5
JP2025503969A5 JP2024544444A JP2024544444A JP2025503969A5 JP 2025503969 A5 JP2025503969 A5 JP 2025503969A5 JP 2024544444 A JP2024544444 A JP 2024544444A JP 2024544444 A JP2024544444 A JP 2024544444A JP 2025503969 A5 JP2025503969 A5 JP 2025503969A5
Authority
JP
Japan
Application number
JP2024544444A
Other languages
Japanese (ja)
Other versions
JP2025503969A (ja
JPWO2023146987A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011654 external-priority patent/WO2023146987A1/en
Publication of JP2025503969A publication Critical patent/JP2025503969A/ja
Publication of JPWO2023146987A5 publication Critical patent/JPWO2023146987A5/ja
Publication of JP2025503969A5 publication Critical patent/JP2025503969A5/ja
Pending legal-status Critical Current

Links

JP2024544444A 2022-01-26 2023-01-26 化合物及び使用方法 Pending JP2025503969A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263303409P 2022-01-26 2022-01-26
US63/303,409 2022-01-26
US202263435210P 2022-12-23 2022-12-23
US63/435,210 2022-12-23
PCT/US2023/011654 WO2023146987A1 (en) 2022-01-26 2023-01-26 Compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2025503969A JP2025503969A (ja) 2025-02-06
JPWO2023146987A5 JPWO2023146987A5 (https=) 2026-02-04
JP2025503969A5 true JP2025503969A5 (https=) 2026-02-04

Family

ID=85328599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544444A Pending JP2025503969A (ja) 2022-01-26 2023-01-26 化合物及び使用方法

Country Status (10)

Country Link
US (1) US20250136594A1 (https=)
EP (1) EP4469438A1 (https=)
JP (1) JP2025503969A (https=)
KR (1) KR20240153335A (https=)
AU (1) AU2023213736A1 (https=)
CA (1) CA3243127A1 (https=)
IL (1) IL314320A (https=)
MX (1) MX2024009177A (https=)
TW (1) TW202339736A (https=)
WO (1) WO2023146987A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525104A (ja) * 2022-07-28 2025-08-01 ベイジン アースワイズ テクノロジー カンパニー リミテッド Prmt5阻害剤
WO2024104244A1 (zh) * 2022-11-15 2024-05-23 四川科伦博泰生物医药股份有限公司 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途
CN120019044A (zh) * 2022-12-22 2025-05-16 成都苑东生物制药股份有限公司 一种取代草酰胺类衍生物、其制备方法及用途
JP2026504087A (ja) * 2023-01-17 2026-02-03 スジョウ・プヘ・バイオファーマ・カンパニー・リミテッド Prmt5-mta阻害剤
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118290386B (zh) * 2024-04-02 2025-06-20 国科大杭州高等研究院 7-羟基黄酮类化合物及其制备方法和应用
WO2025217297A1 (en) 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US11077101B1 (en) * 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
CN116568677A (zh) * 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物

Similar Documents

Publication Publication Date Title
JP2025503969A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307044215S (https=)
BY13135U (https=)
CN307049411S (https=)
CN307048360S (https=)
BY13141U (https=)
CN307048357S (https=)
CN307047583S (https=)
BY13140U (https=)
CN307045930S (https=)
CN307045860S (https=)
CN307045587S (https=)
CN307045539S (https=)
BY13137U (https=)
CN307045358S (https=)
CN307045249S (https=)
CN307044950S (https=)
BY13144U (https=)